Zheng, Meng’s team published research in ACS Applied Bio Materials in 2019 | CAS: 1539-42-0

Bis(pyridin-2-ylmethyl)amine(cas: 1539-42-0) is a secondary amine with two picolyl substituents. As a tridentate ligand this compound provides three nitrogen donors that affords good selectivity for Zn2+ over biologically relevant metals such as Na+, K+, Mg2+ and Ca2+, and leaves coordination sites free for anion binding. Application In Synthesis of Bis(pyridin-2-ylmethyl)amine

The author of 《Bioreducible Zinc(II)-Dipicolylamine Functionalized Hyaluronic Acid Mediates Safe siRNA Delivery and Effective Glioblastoma RNAi Therapy》 were Zheng, Meng; Yang, Zhipeng; Chen, Shizhu; Wu, Haigang; Liu, Yang; Wright, Amanda; Lu, Jeng-Wei; Xia, Xue; Lee, Albert; Zhang, Jinchao; Yin, Huijun; Wang, Yingze; Ruan, Weimin; Liang, Xing-Jie. And the article was published in ACS Applied Bio Materials in 2019. Application In Synthesis of Bis(pyridin-2-ylmethyl)amine The author mentioned the following in the article:

RNA interference (RNAi) is an emerging therapeutic modality for tumors. However, lack of a safe and efficient small interfering RNA (siRNA) delivery system limits its clin. application. Here, we report a bioreducible and less-cationic siRNA delivery carrier by conjugating Zn(II)-dipicolylamine complexes (Zn-DPA) onto hyaluronic acid (HA) via a redox-sensitive disulfide (-SS-) linker. Such polymer conjugates can formulate stable siRNA nanomedicines via coordination between zinc ions of DPA and the anionic phosphate of siRNA. After the conjugates are taken up by cells, intracellular reduction stimulus subsequently triggers the release of siRNAs and elucidates the desired RNAi effect. Our studies showed the formulated siRNA nanomedicines can be efficiently delivered into tumor cells/tissues and mediates less cytotoxicities both in vitro and in vivo. More importantly, when applied in a xenograft glioblastoma tumor model, this siRNA nanomedicine demonstrated significantly enhanced antitumor ability comparing to naked siRNA. This work demonstrates that such bioreducible Zn-DPA-functionalized HA conjugates without using cationic material as a siRNA carrier represents a promising direction for RNAi-based cancer therapy.Bis(pyridin-2-ylmethyl)amine(cas: 1539-42-0Application In Synthesis of Bis(pyridin-2-ylmethyl)amine) was used in this study.

Bis(pyridin-2-ylmethyl)amine(cas: 1539-42-0) is a secondary amine with two picolyl substituents. As a tridentate ligand this compound provides three nitrogen donors that affords good selectivity for Zn2+ over biologically relevant metals such as Na+, K+, Mg2+ and Ca2+, and leaves coordination sites free for anion binding. Application In Synthesis of Bis(pyridin-2-ylmethyl)amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem